Cortexyme, Inc. (CRTX)

NASDAQ: CRTX · IEX Real-Time Price · USD
2.27
-0.10 (-4.22%)
At close: Jun 24, 2022 4:00 PM
2.29
+0.02 (0.88%)
After-hours: Jun 24, 2022 7:57 PM EDT
-4.22%
Market Cap 82.06M
Revenue (ttm) n/a
Net Income (ttm) -88.50M
Shares Out 36.15M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,884,217
Open 2.37
Previous Close 2.37
Day's Range 2.22 - 2.45
52-Week Range 2.22 - 121.98
Beta 1.37
Analysts Sell
Price Target 51.66 (+2,175.8%)
Earnings Date Aug 8, 2022

About CRTX

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San ... [Read more...]

Industry Biotechnology
IPO Date May 9, 2019
Employees 55
Stock Exchange NASDAQ
Ticker Symbol CRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CRTX stock is "Sell." The 12-month stock price forecast is 51.66, which is an increase of 2,175.77% from the latest price.

Price Target
$51.66
(2,175.77% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today annou...

Cortexyme Appoints June Bray to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of Jun...

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with...

Cortexyme Successfully Completes Acquisition of Novosteo

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with...

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with...

Cortexyme Announces Agreement to Acquire Novosteo

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerativ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

NEW YORK , April 25, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Affirm" or the "Company") (NASDAQ: CRTX). Such investors are advised to contac...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class...

NEW YORK--(BUSINESS WIRE)-- #CRTX--WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ...

CRTX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Investigating Cortexyme, Inc. (CRTX) For Possible Secur...

San Francisco, California--(Newsfile Corp. - March 23, 2022) - Hagens Berman urges Cortexyme, Inc. (NASDAQ: CRTX) investors who suffered significant losses to submit your losses now. The firm is investi...

CRTX SHAREHOLDER ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquir...

New York, New York--(Newsfile Corp. - March 21, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexym...

Cortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Mone...

Boston, Massachusetts--(Newsfile Corp. - March 21, 2022) - Block & Leviton is investigating Cortexyme, Inc. (NASDAQ: CRTX) for potential securities law violations. Investors who have lost money in their...

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition i...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagn...

ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action ...

NEW YORK, March 15, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ...

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today

Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest...

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of pati...

Cortexyme to Present New GAIN Trial Data at AD/PD 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of pati...

Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of pati...

Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis

Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.

Cortexyme Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of its Phase 1 Clinical Tria...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of pati...

CRTX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquir...

New York, New York--(Newsfile Corp. - March 6, 2022) - WHY: New York, N.Y., March 6, 2022. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on beha...

ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class Acti...

New York, New York--(Newsfile Corp. - March 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme...

CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and...

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Compa...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors with Losses to Inquire About Securities Class A...

New York, New York--(Newsfile Corp. - February 20, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Corte...

Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact ...

Los Angeles, California--(Newsfile Corp. - February 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Co...

Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi...